Necitumumab Market
The market for Necitumumab was estimated at $612 million in 2024; it is anticipated to increase to $903 million by 2030, with projections indicating growth to around $1.25 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Necitumumab Market Outlook
Revenue, 2024
$612M
Forecast, 2034
$1.17B
CAGR, 2025 - 2034
6.7%
The Necitumumab industry revenue is expected to be around $653.2 million in 2025 and expected to showcase growth with 6.7% CAGR between 2025 and 2034. The market is gaining steady relevance within the oncology therapeutics landscape as the demand for targeted cancer treatment options continues to rise globally. Increasing prevalence of non-small cell lung cancer and growing adoption of precision medicine approaches are supporting its clinical utilization. Healthcare systems are focusing on improving survival outcomes through biomarker-driven therapies, which is strengthening the role of targeted monoclonal antibodies. Expansion of oncology infrastructure, rising cancer screening rates, and improved access to advanced biologics in emerging economies are further contributing to sustained market momentum. Additionally, ongoing clinical emphasis on combination therapies is enhancing treatment effectiveness and reinforcing demand stability across hospital and specialty care settings.
Necitumumab is a recombinant human IgG1 monoclonal antibody designed to target and inhibit epidermal growth factor receptor activity, thereby blocking tumor cell growth and proliferation. It is primarily used in the treatment of advanced squamous non-small cell lung cancer, often in combination with chemotherapy regimens. Administered intravenously in oncology care settings, it is typically prescribed for patients with limited treatment options in advanced disease stages. Its mechanism of action focuses on disrupting EGFR signaling pathways, which are critical in tumor progression. Recent trends driving demand include increasing adoption of targeted biologic therapies, growing use of combination oncology regimens, and improved molecular diagnostic testing that enables better patient selection. Expanding cancer treatment access and rising focus on personalized oncology care are further supporting its clinical relevance in modern oncology practice.
Market Key Insights
The Necitumumab market is projected to grow from $612.2 million in 2024 to $1.17 billion in 2034. This represents a CAGR of 6.7%, reflecting rising demand across Advanced Non-Small Cell Lung Cancer Treatment, Epidermal Growth Factor Receptor Blockade, and Targeted Therapy for Squamous Cell Carcinoma.
Eli Lilly and Company, Roche Holding AG, Amgen Inc. are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Necitumumab market and are expected to observe the growth CAGR of 4.4% to 6.4% between 2024 and 2030.
Emerging markets including Brazil, South Korea and Saudi Arabia are expected to observe highest growth with CAGR ranging between 7.7% to 9.2%.
Transition like Transition from Broad Chemotherapy Regimens to Targeted EGFR-Based Precision Oncology has greater influence in U.S. and Germany market's value chain; and is expected to add $33 million of additional value to Necitumumab industry revenue by 2030.
The Necitumumab market is set to add $559 million between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.
With
advanced research in oncology, and
Increasing Incidence of Lung Cancer, Necitumumab market to expand 91% between 2024 and 2034.
Opportunities in the Necitumumab
The expansion of EGFR biomarker testing across global oncology diagnostic infrastructure is also creating strong growth opportunities for necitumumab. Wider adoption of molecular diagnostics is enabling better identification of patients with EGFR-expressing tumors, improving treatment selection accuracy. This is increasing the clinical relevance of EGFR-targeted therapies in personalized cancer care. Necitumumab benefits directly from improved patient stratification, particularly in advanced squamous non-small cell lung cancer cases. Investments in cancer genomics, precision diagnostics, and hospital laboratory modernization are further accelerating biomarker-driven treatment adoption, especially in developed and rapidly developing healthcare markets.
Growth Opportunities in North America and Asia Pacific
North America remains a significant region for necitumumab adoption due to its advanced oncology infrastructure, high lung cancer diagnosis rates, and strong acceptance of targeted cancer therapies. The region benefits from widespread availability of molecular diagnostics, enabling physicians to identify patients who may benefit from EGFR-targeted treatments. Major growth drivers include increasing investments in precision oncology, rising healthcare expenditure, and continuous clinical research focused on improving outcomes for patients with squamous non-small cell lung cancer. Top opportunities are emerging through combination therapy development, biomarker-based treatment expansion, and integration of targeted biologics into personalized cancer care pathways. Competition is characterized by the presence of established pharmaceutical companies offering immunotherapies, EGFR inhibitors, and other targeted oncology products. Additionally, growing adoption of immune checkpoint inhibitors creates a competitive environment, encouraging manufacturers to demonstrate superior efficacy and value. Strong reimbursement systems, extensive cancer awareness programs, and active participation in oncology clinical trials continue to support market growth across the United States and Canada.
Europe represents an important market for necitumumab, supported by increasing adoption of targeted oncology therapies and well-established public healthcare systems. Growth is driven by rising incidence of lung cancer, expanding access to advanced cancer diagnostics, and growing emphasis on personalized medicine across countries such as Germany, France, Italy, and the United Kingdom. A key opportunity lies in strengthening biomarker-guided treatment strategies, which can improve patient selection and therapeutic outcomes. Additionally, collaborations between pharmaceutical companies, academic research centers, and cancer institutes are creating opportunities for expanded clinical applications and combination treatment studies. Competition remains intense due to the availability of alternative targeted therapies, immunotherapies, and biosimilar products entering the oncology landscape. Regulatory support for innovative cancer treatments and increasing investment in oncology research further stimulate market development. However, pricing pressures and country-specific reimbursement assessments influence market penetration strategies. Despite these challenges, demand for advanced biologic therapies continues to create favorable growth prospects throughout the European oncology sector.
Market Dynamics and Supply Chain
01
Driver: Rising Incidence of Lung Cancer and Expanding Adoption of Targeted Oncology Biologics
The necitumumab market is also primarily driven by the rising incidence of non-small cell lung cancer combined with the expanding adoption of targeted oncology biologics. First, the increasing global burden of lung cancer, particularly squamous NSCLC, is also creating sustained demand for advanced treatment options in late-stage patients with limited alternatives. Second, oncology treatment is also shifting toward precision medicine, where monoclonal antibodies like necitumumab are also preferred due to their ability to selectively inhibit tumor growth pathways such as EGFR signaling. Hospitals and cancer centers are also increasingly integrating biologic-based regimens into standard care protocols. These two factors together are also strengthening clinical reliance on targeted therapies, thereby supporting steady market expansion.
The growing integration of biomarker-driven treatment approaches in lung cancer care is also a key driver for necitumumab. also advances in molecular diagnostics are also enabling oncologists to identify patients with specific EGFR expression profiles, improving treatment selection and therapeutic outcomes. This shift toward personalized oncology is also increasing the clinical relevance of monoclonal antibodies in combination chemotherapy regimens. Additionally, healthcare systems are also increasingly adopting evidence-based treatment protocols that emphasize targeted therapy over conventional chemotherapy alone. As diagnostic capabilities expand and precision oncology becomes more widely implemented, demand for necitumumab in specialized lung cancer treatment settings continues to strengthen globally.
02
Restraint: Limited Clinical Indications and Narrow Patient Eligibility in Lung Cancer Treatment
One of the primary restraints for necitumumab is its limited clinical indication and narrow patient eligibility, which significantly restricts its overall market reach. The drug is specifically approved for advanced squamous non-small cell lung cancer, excluding other major lung cancer subtypes, which reduces its addressable patient pool. For example, patients with adenocarcinoma or other NSCLC variants are not candidates for this therapy, leading to lower prescription volumes. This narrow indication limits hospital adoption and reduces long-term revenue scalability, as oncologists often prefer broader-spectrum therapies that can be applied across multiple cancer subtypes.
03
Opportunity: Growing Oncology Drug Combination Regimens in Emerging Healthcare Economies and Expanding Targeted Therapy Adoption in Advanced Lung Cancer Treatment Centers
The increasing use of combination oncology drug regimens in emerging healthcare economies presents a significant opportunity for necitumumab. As healthcare infrastructure improves in countries such as India, Brazil, and Southeast Asia, hospitals are adopting multi-drug chemotherapy protocols to enhance treatment effectiveness. Necitumumab is increasingly being integrated into combination regimens for advanced lung cancer patients where targeted therapy options are expanding. Rising cancer incidence, improving affordability of biologics, and government support for oncology care programs are further driving demand. This trend is particularly strong in urban cancer centers and tertiary care hospitals across developing regions.
The growing adoption of targeted therapies in advanced lung cancer treatment centers presents a key opportunity for necitumumab. As oncology care shifts toward precision medicine, hospitals are increasingly incorporating monoclonal antibody-based regimens to improve survival outcomes in advanced non-small cell lung cancer patients. Necitumumab, as an EGFR-targeting biologic, is positioned for use in combination chemotherapy protocols, particularly in squamous NSCLC cases. Expansion of specialized oncology centers and improved access to biologic therapies in emerging healthcare systems are further supporting adoption. Increasing physician familiarity with targeted treatment pathways is also enhancing its clinical utilization.
04
Challenge: Strong Competition from Advanced Immunotherapy and Next Generation Targeted Therapies
Another major restraint is the strong competition from rapidly advancing immunotherapy and next-generation targeted cancer treatments. Drugs such as PD-1/PD-L1 inhibitors and newer biologics are increasingly becoming standard-of-care in lung cancer management due to improved survival outcomes and broader applicability. For instance, many oncology centers are shifting treatment protocols toward immunotherapy-based regimens, reducing reliance on older EGFR-targeting antibodies like necitumumab. This shift in clinical preference is leading to declining demand in certain markets, limiting growth potential and intensifying competitive pressure within the oncology biologics landscape.
Supply Chain Landscape
1
Raw Material Acquisition
Eli Lilly and CompanyBristol-Myers Squibb
2
Intermediate Production
Biocon LimitedRoche Diagnostics GmbH
3
Formulation & Packaging
Pfizer Inc.Dr. Reddy's Laboratories Ltd
4
Clinical Trials & Distribution
Innovent Biologics Inc.Merck KGaA
1
Raw Material Acquisition
Eli Lilly and CompanyBristol-Myers Squibb
2
Intermediate Production
Biocon LimitedRoche Diagnostics GmbH
3
Formulation & Packaging
Pfizer Inc.Dr. Reddy's Laboratories Ltd
4
Clinical Trials & Distribution
Innovent Biologics Inc.Merck KGaA
Use Cases of Necitumumab in Advanced Non-Small Cell Lung Cancer Treatment & Epidermal Growth Factor Receptor Blockade
Advanced Non-Small Cell Lung Cancer Treatment : Advanced non-small cell lung cancer treatment represents the primary application of necitumumab, where the drug is used as a recombinant IgG1 monoclonal antibody administered intravenously in combination with platinum-based chemotherapy. It is primarily utilized in hospital oncology departments and cancer treatment centers for patients with advanced or metastatic squamous NSCLC. Its role is to enhance survival outcomes by inhibiting tumor cell proliferation and improving chemotherapy response rates. Oncologists prefer this therapy for patients with limited treatment alternatives, especially in later-stage disease. Growing cancer burden and increasing adoption of targeted biologics in lung cancer care are supporting sustained utilization in this segment.
Epidermal Growth Factor Receptor Blockade : Epidermal growth factor receptor blockade is a key mechanism-based application of necitumumab, where it functions as a targeted EGFR inhibitor to disrupt cancer cell signaling pathways. The therapy is used in specialized oncology settings to prevent tumor growth and progression by blocking ligand binding to EGFR receptors. It is primarily administered in combination with chemotherapy protocols to improve therapeutic efficacy. Oncology specialists leverage this mechanism in patients with EGFR-expressing tumors to enhance treatment precision. Increasing focus on biomarker-driven cancer therapies and improved molecular diagnostic testing is driving adoption of EGFR-targeted monoclonal antibodies, strengthening its role in modern precision oncology strategies.
Targeted Therapy for Squamous Cell Carcinoma : Targeted therapy for squamous cell carcinoma is an important application of necitumumab, particularly in the treatment of advanced-stage lung squamous cell carcinoma. The drug is used as a precision monoclonal antibody therapy in oncology hospitals to specifically inhibit EGFR-mediated tumor growth pathways associated with squamous histology. It is often integrated into first-line treatment regimens alongside chemotherapy to improve patient survival outcomes. This application benefits from rising incidence of squamous NSCLC and increasing preference for targeted biologic therapies over conventional chemotherapy alone. Expanding access to molecular profiling and improved cancer diagnostics is further enhancing patient selection and treatment effectiveness in this segment.
Impact of Industry Transitions on the Necitumumab Market
As a core segment of the Pharmaceutical industry,
the Necitumumab market develops in line with broader industry shifts.
Over recent years, transitions such as Transition from Broad Chemotherapy Regimens to Targeted EGFR-Based Precision Oncology and Transition from Standalone Cancer Treatments to Combination Therapy Strategies have redefined priorities
across the Pharmaceutical sector,
influencing how the Necitumumab market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition from Broad Chemotherapy Regimens to Targeted EGFR-Based Precision Oncology
The necitumumab market reflects a broader transition from conventional chemotherapy approaches toward targeted epidermal growth factor receptor therapies in oncology. Healthcare providers are increasingly adopting biomarker-driven treatment strategies to improve therapeutic outcomes and reduce unnecessary toxicity. Necitumumab, particularly in squamous non-small cell lung cancer (NSCLC), supports this shift by targeting specific molecular pathways involved in tumor growth. This transition is influencing the pharmaceutical industry through increased investment in precision medicine research, while diagnostic companies benefit from rising demand for companion testing and molecular profiling technologies used to identify suitable patient populations.
02
Transition from Standalone Cancer Treatments to Combination Therapy Strategies
The oncology sector is moving from reliance on single-agent treatments toward integrated combination therapy approaches, creating new opportunities for necitumumab. Researchers are evaluating targeted monoclonal antibodies alongside chemotherapy, immunotherapy, and other novel agents to enhance efficacy and overcome resistance mechanisms. This transition is driving collaborations between biopharmaceutical companies, clinical research organizations, and healthcare institutions to develop optimized treatment protocols. For example, combination-based cancer management has increased demand for advanced clinical trial services and personalized treatment planning platforms. As a result, associated industries such as oncology diagnostics, biologics manufacturing, and specialty healthcare services are experiencing growing innovation and investment.